Association of PON1-L55M Genetic Variation and Breast Cancer Risk: A Case-Control Trial.
Aryldialkylphosphatase
/ genetics
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ genetics
Carcinoma, Ductal, Breast
/ genetics
Carcinoma, Lobular
/ genetics
Case-Control Studies
Female
Follow-Up Studies
Genetic Predisposition to Disease
Genotype
Humans
Lymphatic Metastasis
Middle Aged
Neoplasm Invasiveness
Polymorphism, Genetic
Prognosis
Risk Factors
Genetic polymorphism
PCR-RFLP
Paraoxonase 1
breast cancer
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Jan 2020
01 Jan 2020
Historique:
received:
14
11
2019
entrez:
28
1
2020
pubmed:
28
1
2020
medline:
26
9
2020
Statut:
epublish
Résumé
Paraoxonase 1 (PON1), a multifactorial antioxidant enzyme, has a defensive role against oxidative stress, which is believed to contribute to cancer development. This study aimed to investigate the association of PON1-L55M functional polymorphism with breast cancer risk. In the experimental study, blood samples were collected from 150 healthy women controls and 150 breast cancer subjects. The L55M genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism. Our analysis showed that the genotypes distribution is in Hardy-Weinberg equilibrium for both case and control groups. Our data revealed that there are significant associations between PON1-L55M polymorphism and breast cancer risk in homozygote (OR= 2.13, 95%CI= 1.14-4.00, p= 0.018), dominant (OR= 1.72, 95%CI= 1.07-2.76, p= 0.024), and allelic (OR= 1.55, 95%CI= 1.12-2.15, p= 0.008) models. Our results suggest that the PON1-L55M genetic variation could be a genetic risk factor for breast cancer risk and it could be considered as a molecular biomarker for screening of susceptible women.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
Paraoxonase 1 (PON1), a multifactorial antioxidant enzyme, has a defensive role against oxidative stress, which is believed to contribute to cancer development. This study aimed to investigate the association of PON1-L55M functional polymorphism with breast cancer risk.
MATERIAL AND METHODS
METHODS
In the experimental study, blood samples were collected from 150 healthy women controls and 150 breast cancer subjects. The L55M genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism.
RESULTS
RESULTS
Our analysis showed that the genotypes distribution is in Hardy-Weinberg equilibrium for both case and control groups. Our data revealed that there are significant associations between PON1-L55M polymorphism and breast cancer risk in homozygote (OR= 2.13, 95%CI= 1.14-4.00, p= 0.018), dominant (OR= 1.72, 95%CI= 1.07-2.76, p= 0.024), and allelic (OR= 1.55, 95%CI= 1.12-2.15, p= 0.008) models.
CONCLUSIONS
CONCLUSIONS
Our results suggest that the PON1-L55M genetic variation could be a genetic risk factor for breast cancer risk and it could be considered as a molecular biomarker for screening of susceptible women.<br />.
Identifiants
pubmed: 31983193
doi: 10.31557/APJCP.2020.21.1.255
pmc: PMC7294023
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Aryldialkylphosphatase
EC 3.1.8.1
PON1 protein, human
EC 3.1.8.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
255-258Références
Anatol J Cardiol. 2016 Mar;16(3):175-82
pubmed: 26467378
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3066-3075
pubmed: 30072177
Gene. 2015 Aug 1;567(1):12-21
pubmed: 25965560
J Gene Med. 2018 Oct;20(10-11):e3053
pubmed: 30160806
Andrologia. 2018 Nov;50(9):e13081
pubmed: 29968322
Oncotarget. 2018 May 4;9(34):23824-23842
pubmed: 29805775
Biochem Pharmacol. 2005 Feb 15;69(4):541-50
pubmed: 15670573
J Cell Biochem. 2019 Oct;120(10):18020-18030
pubmed: 31144366
Int J Cancer. 2008 Sep 15;123(6):1246-54
pubmed: 18566989
Hum Fertil (Camb). 2019 Jun;22(2):111-117
pubmed: 28974117
Nature. 1998 Jul 16;394(6690):284-7
pubmed: 9685159
IUBMB Life. 2012 Feb;64(2):162-8
pubmed: 22131196
Biomed Res Int. 2019 Jul 28;2019:5897505
pubmed: 31467900
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1226-8
pubmed: 16775186
Reprod Biomed Online. 2019 Apr;38(4):588-598
pubmed: 30738766
Chem Biol Interact. 2006 Mar 10;160(1):1-40
pubmed: 16430879
Nat Commun. 2018 Aug 28;9(1):3490
pubmed: 30154431
Oxid Med Cell Longev. 2010 May-Jun;3(3):168-77
pubmed: 20716941
Gen Pharmacol. 1998 Sep;31(3):329-36
pubmed: 9703197
Gene. 2017 Dec 30;637:161-172
pubmed: 28943344
Tumour Biol. 2016 Apr;37(4):4281-91
pubmed: 26815507
Lancet Oncol. 2001 Mar;2(3):133-40
pubmed: 11902563
Iran J Basic Med Sci. 2018 Jul;21(7):701-708
pubmed: 30140409
J Biol Chem. 2002 Feb 8;277(6):4301-8
pubmed: 11726658
Age (Omaha). 1998 Apr;21(2):47-76
pubmed: 23604352
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52
pubmed: 12433710
Physiol Rev. 1994 Jan;74(1):139-62
pubmed: 8295932